Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Am J Transplant. 2018 Jan;18(1):253-257. doi: 10.1111/ajt.14418. Epub 2017 Aug 14.
Combined liver/kidney transplant is the preferred transplant option for most patients with primary hyperoxaluria type 1 (PH1) since orthotopic liver transplantation replaces the deficient liver-specific AGT enzyme, thus restoring normal metabolic oxalate production. However, primary hyperoxaluria type 2 (PH2) is caused by deficient glyoxylate reductase/hydroxypyruvate reductase (GRHPR), and this enzyme is widely distributed throughout the body. Though the relative abundance and activity of GRHPR in various tissues is not clear, some evidence suggests that the majority of enzyme activity may indeed reside within the liver. Thus the effectiveness of liver transplantation in correcting this metabolic disorder has not been demonstrated. Here we report a case of 44-year-old man with PH2, frequent stone events, and end-stage renal disease; he received a combined liver/kidney transplant. Although requiring confirmation in additional cases, the normalization of plasma oxalate, urine oxalate, and urine glycerate levels observed in this patient within a month of the transplant that remain reduced at the most recent follow-up at 13 months suggests that correction of the GRHPR deficiency in PH2 can be achieved by liver transplantation.
联合肝/肾移植是大多数 1 型原发性高草酸尿症(PH1)患者的首选移植方案,因为原位肝移植可替代缺乏的肝脏特异性 AGT 酶,从而恢复正常的代谢草酸生成。然而,2 型原发性高草酸尿症(PH2)是由甘油酸还原酶/羟丙酮酸还原酶(GRHPR)缺乏引起的,这种酶广泛分布于全身。尽管各种组织中 GRHPR 的相对丰度和活性尚不清楚,但有一些证据表明,大部分酶活性可能确实存在于肝脏中。因此,肝移植纠正这种代谢紊乱的效果尚未得到证实。本文报告了 1 例 44 岁 PH2 男性患者,频繁结石事件和终末期肾病,他接受了联合肝/肾移植。尽管需要在更多病例中证实,但该患者在移植后 1 个月内观察到血浆草酸、尿草酸和尿甘油酸水平正常化,并且在最近的 13 个月随访时仍保持降低,这表明肝移植可以纠正 PH2 中的 GRHPR 缺乏。